Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Equity?
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 77 Debt-to-Equity is 0.80 as of Mar. 2026, which is 8% above its 10-year median of 0.74. GuruFocus rates SFOSF with a GF Score™ of 77/100 and a GF Value™ of $2.79 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 812 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks worse than 81.28% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Equity Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Equity Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Debt-to-Equity of 0.80 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is near median its historical median of 0.74. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Equity has ranged from 0.51 to 0.90. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #660 out of 812 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Equity too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-Equity of 0.80 is near median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 0.90. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.80 is 196.3% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #660 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #660 out of 812 companies for Debt-to-Equity. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Shanghai Fosun Pharmaceutical (Group) Co's value of 0.80 is 196.3% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Debt-to-Equity has ranged from 0.51 to 0.90 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 0.27, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-Equity of 0.80 is 196.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-Equity is 0.80, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.79, compared to a current price of $2.20 — trading 21.1% below its estimated fair value. The current Debt-to-Equity is 0.80, which is near median its 10-year median of 0.74 and 196.3% above the Drug Manufacturers industry median of 0.27. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Debt-to-Equity is 0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 21.1% below its estimated GF Value™ of $2.79.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Debt-to-Equity: 0.80 (near median its 10-year median of 0.74)
GF Value™: $2.79 vs. price of $2.20 (21.1% below fair value)
Industry Position: 196.3% above the Drug Manufacturers median (#660 of 812)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
